MedPath

Benefits and safety of high flow nasal oxygen in mild to moderate acute hypoxemic respiratory failure at medical ward, a randomized trial

Phase 4
Recruiting
Conditions
Adult inpatients who were admitted in medical general wards with the diagnosis mild to moderate acute hypoxia.
high flow nasal oxygen&#44
moderate acute hypoxia&#44
Registration Number
TCTR20180130001
Lead Sponsor
no
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

all the following
1.Mild to moderate acute hypoxemic respiratory failure(table)
2.Admitted at general medical wards
3.Age >18 years old
Definition of mild to moderate hypoxemic respiratory failure
•Respiratory rate >25 breaths/min and/or increased work of breathing, evidenced by clinical signs (dyspnea, use of accessory muscles of respiration, diaphoresis) AND
•Requiring >4 L/min O2 via nasal cannula or requiring O2 therapy equivalent to
FiO2 >0.4 to keep PaO2 >60 mmHg or SpO2 >90% for >1 hour

Exclusion Criteria

1.PaCO2 >45 mmHg
2.Post-extubation respiratory failure (respiratory failure within 48 hr after extubation)
3.Life-threatening ARF requiring immediate IMV
4.Shock
5.Contraindications to NIV
6.A do-not-intubate order
7.Patients refused to participate the study
8.Intra-abdominal hypertension
9.Pulmonary tuberculosis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rate of required NIV or IMV within 48 hours after randomization within 48 hours after randomization Number of subject who need NIV or IMV initiation within 48 hours after randomization
Secondary Outcome Measures
NameTimeMethod
30-day mortality 30 day Number of subject died at 30 day after randomization
© Copyright 2025. All Rights Reserved by MedPath